229 related articles for article (PubMed ID: 19225035)
1. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
3. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood.
Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Gooren L; Ernst M
Aging Male; 2009 Dec; 12(4):113-8. PubMed ID: 19909203
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
5. The effects of exogenous testosterone on sexuality and mood of normal men.
Anderson RA; Bancroft J; Wu FC
J Clin Endocrinol Metab; 1992 Dec; 75(6):1503-7. PubMed ID: 1464655
[TBL] [Abstract][Full Text] [Related]
6. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
7. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
[TBL] [Abstract][Full Text] [Related]
8. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
10. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
11. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men.
Anderson RA; Martin CW; Kung AW; Everington D; Pun TC; Tan KC; Bancroft J; Sundaram K; Moo-Young AJ; Baird DT
J Clin Endocrinol Metab; 1999 Oct; 84(10):3556-62. PubMed ID: 10522995
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
[TBL] [Abstract][Full Text] [Related]
14. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose.
O'Carroll R; Shapiro C; Bancroft J
Clin Endocrinol (Oxf); 1985 Nov; 23(5):527-38. PubMed ID: 3910302
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
[TBL] [Abstract][Full Text] [Related]
16. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
Wang C; Harnett M; Dobs AS; Swerdloff RS
J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
[TBL] [Abstract][Full Text] [Related]
18. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.
Yassin AA; Saad F
J Sex Med; 2007 Mar; 4(2):497-501. PubMed ID: 17367445
[TBL] [Abstract][Full Text] [Related]
19. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
20. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]